1 |
ClinicalTrials.gov (NCT02414880) Sugammadex Versus Neostigmine in Patients With Liver Cirrhosis Undergoing Liver Resection
|
2 |
Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
|
3 |
Neostigmine FDA Label
|
4 |
Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
|
5 |
Screening of acetylcholinesterase inhibitors by CE after enzymatic reaction at capillary inlet. J Sep Sci. 2009 May;32(10):1748-56.
|
6 |
Improving the prediction of the brain disposition for orally administered drugs using BDDCS. Adv Drug Deliv Rev. 2012 Jan;64(1):95-109.
|
7 |
Hairy-root organ cultures for the production of human acetylcholinesterase. BMC Biotechnol. 2008 Dec 23;8:95.
|
8 |
Fresh frozen plasma transfusion for reversal of prolonged post-anaesthesia apnoea. Transfus Med. 2008 Apr;18(2):134-6. doi: 10.1111/j.1365-3148.2008.00851.x.
|
9 |
Pharmacological characteristics of the inhibition of nondepolarizing neuromuscular blocking agents at human adult muscle nicotinic acetylcholine receptor. Anesthesiology. 2009 Jun;110(6):1244-52.
|
10 |
Polyspecific organic anion transporting polypeptides mediate hepatic uptake of amphipathic type II organic cations. J Pharmacol Exp Ther. 1999 Oct;291(1):147-52.
|
11 |
Drug Interactions in Infectious Diseases.
|
12 |
ClinicalTrials.gov (NCT00675792) Comparison of Sugammadex Administered at 1-2 Post Tetanic Counts (PTCs) or Better With Neostigmine Administered as Per Standard of Care to Reverse Rocuronium-Induced Neuromuscular Blockade in Adults Undergoing Elective Open Abdominal Procedure (19.4.334) (P05774)
|
|
|
|
|
|
|